These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12141889)

  • 1. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
    Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
    Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
    Groenendaal H; Tarrants ML; Armand C
    Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.
    Hansen RN; Suh K; Serbin M; Yonan C; Sullivan SD
    J Med Econ; 2021; 24(1):563-569. PubMed ID: 33866942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
    Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
    J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
    Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
    Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
    Iansek R; Danoudis M
    Parkinsonism Relat Disord; 2011 Aug; 17(7):533-6. PubMed ID: 21576031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.
    Delea TE; Thomas SK; Hagiwara M
    CNS Drugs; 2011 Jan; 25(1):53-66. PubMed ID: 21128694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.
    Kupsch A; Trottenberg T; Bremen D
    Curr Med Res Opin; 2004 Jan; 20(1):115-20. PubMed ID: 14741081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
    Destée A; Rérat K; Bourdeix I
    Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
    Damier P; Viallet F; Ziegler M; Bourdeix I; Rerat K
    Eur J Neurol; 2008 Jul; 15(7):643-8. PubMed ID: 18582341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
    Brooks DJ; Sagar H;
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1071-9. PubMed ID: 12876237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.